Accelerating Breakthrough Discoveries into Medicines

Alzheimer’s Drug Discovery Foundation

ADDF-Harrington Scholar Program

Alzheimer's Drug Discovery Foundation

The ADDF-Harrington Scholar Award was created to accelerate translation of innovative research efforts that could prevent, treat, or cure Alzheimer’s disease. The ADDF-Harrington Scholar Award Program is a collaboration between the Alzheimer’s Drug Discovery Foundation (ADDF) and Harrington Discovery Institute. Please note that this is a special funding opportunity separate from ADDF’s Core Funding Programs.

Award Details

  • Funding up to $600,000 over two years
  • Drug development and project management support through the Harrington Discovery Institute’s Innovation Support Center team of pharmaceutical experts

Eligibility Criteria

  • Academic investigators at accredited medical centers, research institutions, and universities in the United States only are eligible to apply
  • Lead investigator must have an MD and/or PhD (or equivalent)
  • Proposals should support the development of a small molecule or biologic to treat, prevent or slow Alzheimer’s disease, other dementias, and cognitive aging
  • Novel targets are particularly encouraged
  • The ideal project will be at stage of active hit-to-lead optimization
  • Team should possess intellectual property (IP), have identified protection strategy, and have potential to be developed into a commercializable project

Areas of Interest

Our current target areas of interest include, but are not limited to:

  • Neuroprotection
  • Neuroinflammation
  • Neuronal Energy Failure
  • ApoE and Vascular
  • Epigenetics
  • Cognitive Enhancers
  • Aberrant Signaling
  • Autophagy

Areas of limited interest include:

Anti-amyloid approaches, including anti-amyloid aggregation programs, Abeta vaccine development, beta or gamma-secretase inhibition programs, and cholinesterase inhibitor programs.

Application Submission

All applications must be submitted online at AlzDiscovery.org/RFPs.

Projects will be assessed based on:

  • Quality of the science and the scientist
  • Novelty and innovative quality of the work
  • Potential for impact on human health

Deadlines

Letter of Intent: March 17, 2017, 11:59 PM EST

Full Proposal: July 14, 2017, 11:59 PM EST